These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38530568)

  • 1. Efficacy, Safety and Immunogenicity of Sun's Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study.
    Ghosh AK; Nikumbh US; Shukla CK; Laul RS; Dixit A; Mahapatra SK; Nayak S; Shah UM; Parwal S; Venkatapathy N; Radhakrishnan N; Kelgaonkar A; Saxena S; Mishra D; Dave VP; Khan P; Saswade MR; Shantilal MS; Ramasamy K; Sreekanta S; Rajurkar M; Doshi M; Behera S; Patel P; Dhawan S; Lakhwani L
    Ophthalmol Ther; 2024 May; 13(5):1369-1382. PubMed ID: 38530568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Loewenstein A; Czumbel N; Ernest J; Dusová J; Pearlman J; Nowosielska A
    Ophthalmol Retina; 2023 Sep; 7(9):753-761. PubMed ID: 37179017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis
    Singh R; Chauhan R; Saxena A; Shah A; Mondal L; Bakhle D; Shah C; Shah A; Deoghare S; Krishnan N; Godse N
    Indian J Ophthalmol; 2022 Aug; 70(8):3008-3014. PubMed ID: 35918962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
    Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
    JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of Razumab™ (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study.
    Sharma S; Gupta V; Maiti A; Natesh S; Saxena S; Dave V; Parmar V; Sampangi R; Murthy H; Dharwadkar S; Yadav NK; Joshi S; Mayor R; Ratra D; Basu S; Goel N; Chaturvedi A; Patel R; Jose V
    Int J Retina Vitreous; 2021 Mar; 7(1):24. PubMed ID: 33762008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
    Woo SJ; Bradvica M; Vajas A; Sagong M; Ernest J; Studnicka J; Veith M; Wylegala E; Patel S; Yun C; Orski M; Astakhov S; Tóth-Molnár E; Csutak A; Enyedi L; Kim T; Oh I; Jang H; Sadda SR
    JAMA Ophthalmol; 2023 Jul; 141(7):668-676. PubMed ID: 37289448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial.
    Yoon CK; Oh J; Bae K; Park UC; Yu KS; Yu HG
    PLoS One; 2022; 17(11):e0275611. PubMed ID: 36374913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
    Bressler NM; Kim T; Oh I; Russo P; Kim MY; Woo SJ
    JAMA Ophthalmol; 2023 Feb; 141(2):117-127. PubMed ID: 36520462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised, Double-blind, Comparative Clinical Study of New Ranibizumab Biosimilar in Neovascular (Wet) Age-Related Macular Degeneration.
    Apsangikar P; Ghadge P; Naik M; Nair S; Payghan R
    Clin Ophthalmol; 2021; 15():3087-3095. PubMed ID: 34295147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
    JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
    Bressler NM; Veith M; Hamouz J; Ernest J; Zalewski D; Studnička J; Vajas A; Papp A; Vogt G; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Oh I; Jeong H; Kim MY; Woo SJ
    Br J Ophthalmol; 2023 Mar; 107(3):384-391. PubMed ID: 34656987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial.
    Li B; Fan K; Zhang T; Wu Z; Zeng S; Zhao M; Ren Q; Zheng D; Wang L; Liu X; Han M; Song Y; Ye J; Pei C; Yi J; Wang X; Peng H; Zhang H; Zhou Z; Liang X; Yu F; Wu M; Li C; Lei C; Hao J; Tang L; Yuan H; Cai S; Li Q; Zhong J; Li S; Liu L; Ke M; Wang J; Wang H; Zhu M; Wang Z; Yan Y; Wang F; Chen Y
    Ophthalmol Ther; 2024 Jan; 13(1):353-366. PubMed ID: 37987893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.
    Khurana RN; Kunimoto D; Yoon YH; Wykoff CC; Chang A; Maturi RK; Agostini H; Souied E; Chow DR; Lotery AJ; Ohji M; Bandello F; Belfort R; Li XY; Jiao J; Le G; Kim K; Schmidt W; Hashad Y;
    Ophthalmology; 2021 Jul; 128(7):1027-1038. PubMed ID: 33221326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C;
    Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
    Chan CK; Lalezary M; Abraham P; Elman M; Beaulieu WT; Lin SG; Khurana RN; Bansal AS; Wieland MR; Palmer JD; Chang LK; Lujan BJ; Yiu G;
    Ophthalmol Retina; 2022 Jun; 6(6):484-494. PubMed ID: 35121216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
    JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.